Adropin levels and its associations as a fat-burning hormone in patients with polycystic ovary syndrome: a correlational meta-analysis

• Published in: Gynecological endocrinology 2021-10, Vol.37 (10), p.879-884
• Main Authors: Varikasuvu, Seshadri Reddy, Reddy, E. Prabhakar, Thangappazham, Balachandar, Varshney, Saurabh, Das, Vanita Lal, Munikumar, Manne
• Format: Article
• Language: English
• Subjects: Adropin; Body Mass Index; Dyslipidemias - blood; Dyslipidemias - metabolism; Female; Follicular Fluid - chemistry; Humans; insulin resistance; Insulin Resistance - physiology; Intercellular Signaling Peptides and Proteins - analysis; Intercellular Signaling Peptides and Proteins - blood; meta-analysis; Overweight - blood; Overweight - complications; Overweight - metabolism; polycystic ovary syndrome; Polycystic Ovary Syndrome - blood; Polycystic Ovary Syndrome - complications; Polycystic Ovary Syndrome - metabolism
• ISSN: 0951-3590; 1473-0766
• DOI: 10.1080/09513590.2021.1950136

Adropin is a peptide hormone with potential implications in patients with polycystic ovary syndrome (PCOS). The aim of this meta-analysis was to compare the circulating (serum/plasma) and follicular fluid adropin levels between human PCOS patients and non-PCOS controls. Relevant studies were retrieved by online database and manual searching. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) were obtained by a random-effects meta-analysis. Meta-analysis of correlations was performed for the associations of adropin with anthropometric, lipid, insulin resistance and hormonal covariates. The funnel plot analysis with Begg's and Egger's tests was used for publication bias. A total of 9 studies were included in this meta-analysis. The results indicated that the adropin levels were significantly decreased in PCOS patients as compared to non-PCOS controls (SMD = −1.87, 95% CI = −2.55 to −1.18, p